Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen straight to the gut: new hope for bowel disease?

NCT ID NCT07621367

Disease control Sponsor: The Second Hospital of Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests if delivering oxygen directly into the gut through a thin tube can help people with ischemic-hypoxic bowel disease, a condition where the bowel doesn't get enough oxygen. About 90 adults with symptoms like belly pain, bloating, and trouble pooping will receive either the oxygen therapy or a placebo. The goal is to see if this treatment safely reduces symptoms and improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Definite diagnosis of chronic heart failure or obstructive sleep apnea (OSA) with chronic hypoxia; * Comorbid intestinal dysmotility (abdominal distension, constipation, diarrhea, or abdominal pain); * Disease duration ≥1 month with poor response to conventional treatment; * Tolerability of transendoscopic enteral tubing (TET) with successful placement of the tube at the ileocecal junction; * Age 18-80 years; * Able to cooperate with bed rest therapy and provide written informed consent. Exclusion Criteria: * Oxygenation index \>400 without supplemental oxygen and/or resting oxygen saturation ≥96%; * Primary organic gastrointestinal diseases, intestinal obstruction, inflammatory bowel disease, or severe hepatic/renal failure; * Hemodynamically unstable, unable to tolerate sequential intervention (time-sequenced intervention); * Presence of cough or spinal disorders that prevent maintaining a resting state during bed rest; * Failure of arterial catheterization or endoscopic tube placement; * Mental or cognitive impairment that precludes cooperation with assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic ischemic-hypoxic enteropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Abdominal Pain chronic intestinal vascular insufficiency heart failure ischemic bowel disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic ischemic-hypoxic enteropathy Hypoxic events Ischemic bowel disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.